赛伦生物：公司将结合自身发展需求及外部环境条件，持续关注并积极寻求优质的并购标的

证券日报 01-30

登录新浪财经APP 搜索【信披】查看更多考评等级证券日报网讯 1月30日，赛伦生物在互动平台回答投资者提问时表示，公司第四季度营业收入较低，从而影响了单季度利润。主要原因系公司主要产品抗蛇毒血清和马破伤风免疫球蛋白的适应症发生率具有显著的季节性，蛇伤、外伤均在夏季高发，第二、三季度销量较大，第一、四季度销量较小，各季度的销售收入随之呈现出显著的季节性起伏。公司将结合自身发展需求及外部环境条件，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2607015012?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-01-30 19:06","share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","id":"2607015012","market":"fut","top_or_hot":-1,"title":"赛伦生物：公司将结合自身发展需求及外部环境条件，持续关注并积极寻求优质的并购标的","media":"证券日报 ","content":"<div>\n<p>登录新浪财经APP 搜索【信披】查看更多考评等级\n证券日报网讯 1月30日，赛伦生物在互动平台回答投资者提问时表示，公司第四季度营业收入较低，从而影响了单季度利润。主要原因系公司主要产品抗蛇毒血清和马破伤风免疫球蛋白的适应症发生率具有显著的季节性，蛇伤、外伤均在夏季高发，第二、三季度销量较大，第一、四季度销量较小，各季度的销售收入随之呈现出显著的季节性起伏。公司将结合自身发展需求及外部环境条件，...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/relnews/cn/2026-01-30/doc-inhkauvf3557333.shtml\">网页链接</a>\n\n</div>\n","source":"sina","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>赛伦生物：公司将结合自身发展需求及外部环境条件，持续关注并积极寻求优质的并购标的</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n赛伦生物：公司将结合自身发展需求及外部环境条件，持续关注并积极寻求优质的并购标的\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-30 19:06 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.sina.com.cn/stock/relnews/cn/2026-01-30/doc-inhkauvf3557333.shtml><strong>证券日报 </strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>登录新浪财经APP 搜索【信披】查看更多考评等级\n证券日报网讯 1月30日，赛伦生物在互动平台回答投资者提问时表示，公司第四季度营业收入较低，从而影响了单季度利润。主要原因系公司主要产品抗蛇毒血清和马破伤风免疫球蛋白的适应症发生率具有显著的季节性，蛇伤、外伤均在夏季高发，第二、三季度销量较大，第一、四季度销量较小，各季度的销售收入随之呈现出显著的季节性起伏。公司将结合自身发展需求及外部环境条件，...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/relnews/cn/2026-01-30/doc-inhkauvf3557333.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-01-30/doc-inhkauvf3557333.shtml","article_id":"2607015012","we_media_id":null,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-01-30/doc-inhkauvf3557333.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2607015012","pubTimestamp":1769771160,"columns":[],"sourceInfo":{"source_id":"sina","name":"sina"},"weMediaInfo":null,"summary":"主要原因系公司主要产品抗蛇毒血清和马破伤风免疫球蛋白的适应症发生率具有显著的季节性，蛇伤、外伤均在夏季高发，第二、三季度销量较大，第一、四季度销量较小，各季度的销售收入随之呈现出显著的季节性起伏。公司将结合自身发展需求及外部环境条件，持续关注并积极寻求优质的并购标的，促进公司主业的外延式发展。","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688163":"赛伦生物","BK0239":"医药制造"},"translate_title":"Salen Biotech: The company will continue to pay attention to and actively seek high-quality M&A targets based on its own development needs and external environmental conditions","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688163":1.5},"content_text":"登录新浪财经APP 搜索【信披】查看更多考评等级\n证券日报网讯 1月30日，赛伦生物在互动平台回答投资者提问时表示，公司第四季度营业收入较低，从而影响了单季度利润。主要原因系公司主要产品抗蛇毒血清和马破伤风免疫球蛋白的适应症发生率具有显著的季节性，蛇伤、外伤均在夏季高发，第二、三季度销量较大，第一、四季度销量较小，各季度的销售收入随之呈现出显著的季节性起伏。公司将结合自身发展需求及外部环境条件，持续关注并积极寻求优质的并购标的，促进公司主业的外延式发展。公司严格遵循信息披露法规，若有明确并购计划且达到信息披露标准，将严格按照相关规定及时履行信息披露义务，相关信息请以公司对外披露的公告为准。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2607015012","isCrawlerRequest":true}